SAN FRANCISCO, Oct. 29, 2021 /PRNewswire/ — Castlight Health, Inc. (NYSE:CSLT), a leader in healthcare navigation, today announced that Maeve O’Meara, chief executive officer, and Will Bondurant, chief financial officer, will participate in the Credit Suisse 30th Annual Healthcare Conference, including a fireside chat on Tuesday, November 9, 2021 at 3:30 pm ET. The webcast and related presentation materials will be available on the Investor Relations section of www.castlighthealth.com.
About Castlight Health
Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system and live happier, healthier, more productive lives. As a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical and benefits experts to help members easily connect and engage with the right programs and care, at the right time. Castlight partners with Fortune 500 companies and health plans to transform employee and member benefits into one comprehensive health and wellbeing experience to deliver better health outcomes and maximize returns on healthcare investments.
For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and like us on Facebook.
Castlight Media Contact:
Caroline Kawashima
press@castlighthealth.com
415-246-0313
Castlight Investor Contact:
ir@castlighthealth.com
443-213-0500
View original content to download multimedia:https://www.prnewswire.com/news-releases/castlight-health-to-participate-in-upcoming-investor-conference-301411410.html
SOURCE Castlight Health, Inc.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…